Managers / Q1 2026
Royalty Pharma Sub-Manager, LLCNEW FILER
CIK 0002081668 · 110 E. 59TH STREET, SUITE 3300, NEW YORK, NY, 10022 · 212-883-0200
Summary
Royalty Pharma Sub-Manager, LLC reported $173M in U.S.-listed holdings across 4 positions for Q1 2026.
The portfolio is heavily concentrated: CYTK alone accounts for 37.4% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 85.6% · $148M
- Other · 14.4% · $25M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CYTKCYTOKINETICS, INC | NEW | +980.4K | 980.4K | +$65M | $65M |
| BCAXZENAS BIOPHARMA, INC. | NEW | +2.39M | 2.39M | +$47M | $47M |
| BCRXBIOCRYST PHARMACEUTICALS INC | NEW | +3.85M | 3.85M | +$37M | $37M |
| BIOHAVEN LTD | NEW | +2.94M | 2.94M | +$25M | $25M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CYTKCYTOKINETICS, INChistory → | COM | 37.40% | $65M | 980.4K |
| 2 | BCAXZENAS BIOPHARMA, INC.history → | COM | 27.02% | $47M | 2.39M |
| 3 | BCRXBIOCRYST PHARMACEUTICALS INChistory → | COM | 21.19% | $37M | 3.85M |
| 4 | BIOHAVEN LTD | COM | 14.38% | $25M | 2.94M |
Filing History
Other Included Managers
This filing reports holdings on behalf of 2 additional managers.
- Royalty Pharma Manager, LLC
- Royalty Pharma plc
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.